Abstract
The present Industry Update covers the period 1–31 May 2018. Sources of information included company press releases, regulatory and patent agency notices and various news websites. Regulatory approvals of this month include Novartis (Basel, Switzerland) and Amgen's (CA, USA), Aimovig as a preventive treatment for migraines and Breckenridge's (CO, USA) delayed-release capsules, Duloxetine. This month also saw DURECT (CA, USA) and Sandoz (Upper Bavaria, Germany) renegotiate their agreement for the development, manufacture and commercialization of the extended-release depot product POSIMIR®. In early stage preclinical development news there were several articles published on the area of modified delivery of therapeutics, including across the blood–brain barrier and the development of a novel single dose vaccine for polio.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
